ArticlePharmaceuticals (Basel, Switzerland)2023
Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- 4% 5-Fluorouracil Cream for Actinic Keratoses: First Report of Efficacy and Tolerability in a Person Living With Human Immunodeficiency Virus Infection.Clinical case reports · 2026Article
- Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis.Life (Basel, Switzerland) · 2026Article
- Sequential Keratolytic Pre-Treatment Followed by Tirbanibulin in Hyperkeratotic Actinic Keratoses: A Retrospective Comparative Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study).Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Tirbanibulin 1% Ointment for the Treatment of Hyperkeratotic Actinic Keratosis.The Journal of dermatology · 2025Article
- Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights.Dermatology practical & conceptual · 2025Review
- Field Cancerization Treatment with Tirbanibulin 1% Ointment: Results in Real-World Practice.Acta dermato-venereologica · 2025Article
- Clinical and experimental aspects of tirbanibulin treatments.Archives of dermatological research · 2025Review
- Exploring Anti-Aging Effects of Topical Treatments for Actinic Keratosis.Medicina (Kaunas, Lithuania) · 2025Review
- The Skin-Lightening Power of Tirbanibulin 1% Ointment.Dermatology and therapy · 2025Article
- Role of Nicotinamide in the Pathogenesis of Actinic Keratosis: Implications for NADBiomolecules · 2024Article
- [Update in the diagnosis and treatment of actinic keratosis].Dermatologie (Heidelberg, Germany) · 2024Review
- Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.Dermatology practical & conceptual · 2024Review
- Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience.Dermatology and therapy · 2024Article
- Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study.Medicina (Kaunas, Lithuania) · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActinic keratosis is a common precancerous skin lesion that can progress into invasive squamous cell carcinomas. Many topical treatments for actinic keratoses often have poor tolerability and prolonged duration. Tirbanibulin is a novel synthetic drug with potent antitumor and antiproliferative activities.
methodsWe conducted a single-center, prospective and observational study using tirbanibulin ointment on a 25 cm
resultsOn day 57, 70% of the patients showed a complete clinical and dermoscopic response. The highest scores obtained from the TSQM 1.4 were more evident in the convenience and side effects domains. Most LSRs, including erythema (83.3%), scaling (30%), and swelling (3.3%), occurred on day 8 but resolved spontaneously.
conclusionTirbanibulin is a viable therapeutic option with a short regimen treatment and good tolerability, which favors therapy adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.